What is LOPJLB’s current signal on CRVO?

LOPJLB’s latest quantitative signal on CervoMed Inc. (CRVO) is BUY in a CRISIS regime. Signals are updated daily.

What market regime is CRVO in?

CervoMed Inc. (CRVO) is currently classified in the CRISIS HMM market regime on LOPJLB.

CervoMed Inc. (CRVO)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$2.27-9.56%Close

BUYCRISIS · day 2

RANGE

LOPJLB.COM

OHLCEMALEVELSSTOPFLIP52WSIGNALSBUYSELLEXHEXH ZONECOIL

Key stats

Short interest · FINRA settlement 2026-09-30

Market cap: $21M
Beta: -4.31
P/E (TTM): -0.71

Short % float: 22.11%
Days to cover: 7.0
SI change: +9.1%

1W: -32.04%
1M: -10.28%

vs SPY 1W: -31.90%
vs SPY 1M: -12.78%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodâbrain barrier…

Employees: 15
Headquarters: US
Founded: 2008
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 9.3M
Float: 65.5%

cervomed.com ↗

Key executives

John J. Alam — Co-Founder, Chief Executive Officer, President & Director

William Robert Elder — Chief Financial Officer, General Counsel & Corporate Secretary

Kelly Blackburn — Executive Vice President of Clinical Development

SEC filings

EDGAR · CIK 10536910 · CRVO

Analyst consensus

Buy

Bullish7100.0%

Neutral00.0%

Bearish00.0%

L $7.00Avg $7.00H $7.00

Target$7.00+208.37%

Last$2.27

FAQ

What is LOPJLB’s current signal on CRVO?: LOPJLB’s latest quantitative signal on CervoMed Inc. (CRVO) is BUY in a CRISIS regime. Signals are updated daily.
What market regime is CRVO in?: CervoMed Inc. (CRVO) is currently classified in the CRISIS HMM market regime on LOPJLB.
What does CervoMed Inc. (CRVO) do?: CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodâbrain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, an…

Key stats

Prediction markets

Company news

FAQ